Effect of growth hormone on the low level of growth hormone binding protein in idiopathic short stature.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Growth hormone receptor status was assessed in children with idiopathic short stature by evaluating plasma growth hormone-binding protein before and under GH therapy.

Who Took Part

According to the abstract, 22 children were involved.

PubMed indexes the participants as young children and children, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

They presented growth retardation of -2.8 +/- 0.1 SDS (mean +/- SEM).

All had normal GH secretion and their mean IGF-I plasma level was normal.

Growth hormone-binding protein was measured using high pressure liquid chromatography gel filtration.

The specific binding of 125I-hGH to the growth hormone-binding protein was expressed as a percentage of the total radioactivity.

What Was Measured

Topics PubMed links to this paper include Carrier Proteins, Chromatography, High Pressure Liquid, Growth, Growth Disorders, Growth Hormone, Insulin-Like Growth Factor I and Receptors, Somatotropin.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 22 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1992 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.